Thursday 16 October, 2025
Objectives: Fosfomycin is a potential component of empiric antimicrobial treatment where resistance to ampicillin or cefotaxime/gentamicin (SOC) is high1. Fosfomycin…
Read moreAbstracts
Model based estimation of posaconazole tablet and suspension oral bioavailability using real world electronic health record (EHR) and therapeutic drug monitoring (TDM) data in children.
Thursday 16 October, 2025
Objectives: Invasive fungal infections (IFIs) are a major cause of morbidity and mortality for immunocompromised patients undergoing both solid organ…
Read moreDose dependence of safety of PD-1 and CTLA-4 checkpoint inhibitors: Comparison of normal-normal and binomial-normal hierarchical models for rare events in a Bayesian meta-analysis framework
Thursday 16 October, 2025
Introduction: Immune checkpoint inhibitors (ICIs) are promising anti-cancer therapies; yet, they are associated with immune-mediated adverse events (imAE), especially in…
Read moreLassa viral dynamics in macaques treated with favipiravir or ribavirin
Thursday 16 October, 2025
Objectives: Lassa fever is a potentially lethal/disabling hemorrhagic fever, endemic in West Africa, caused by Lassa virus (LASV), that afflicts…
Read moreModelling SARS-CoV-2 viral dynamics in hospitalized patients: implications for therapeutic evaluation
Thursday 16 October, 2025
Context: In the last two decades, modelling has largely contributed to unravel the determinants of host/pathogen interaction of viral infections,…
Read moreExploring the impact of obesity on drug clearance using PBPK modelling approaches: influential variables affecting scaling from non-obese to obese subjects for drugs metabolized in the liver
Thursday 16 October, 2025
Objectives: Determining drug clearance (CL) is important to establish drug dosing. In the obese, some drugs do not show any…
Read moreVancomycin clearance in obese adults is not predictive of clearance in obese adolescents
Thursday 16 October, 2025
Objectives: Contradictory pharmacokinetic (PK) results have been observed between obese adults and obese adolescents for hepatically cleared drugs, with propofol…
Read moreCachexia-associated anticancer drug toxicity is minimally mediated by alteration of drug’s pharmacokinetics: Erlotinib as case study
Thursday 16 October, 2025
Introduction Cachexia is an irreversible condition of muscle mass loss characterised by chronic systemic inflammation and energy imbalance. It commonly…
Read moreA joint tumour dynamics and C-reactive protein turnover model to identify early longitudinal prognostic predictors of overall survival in advanced non-small cell lung cancer patients
Thursday 16 October, 2025
Background C-reactive protein (CRP), a marker of inflammation, positively correlates with disease aggressiveness and poor prognosis in advanced cancers including…
Read moreQuantifying the dynamics of the modulatory effect of CYP3A perpetrators on hepatic CYP3A activity using a nonlinear mixed-effects model of microdosed midazolam and its metabolite 1-hydroxymidazolam
Thursday 16 October, 2025
Introduction: Cytochrome (CYP) 3A, the most abundant subfamily of CYP450 enzymes, is responsible for the metabolism of ~50% of marketed…
Read more